Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterized by the thickening and stiffening of lung tissue, which makes it increasingly difficult to breathe over time.
Idiopathic Pulmonary Fibrosis: Buloxibutid Study
We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 40 years old or older?
- Do you have a diagnosis of idiopathic pulmonary fibrosis (IPF)?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications for IPF, like pirfenidone, or have you stopped taking them for more than 8 weeks?
- Do you have any serious health conditions, like severe heart problems or liver disease?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Buloxibutid
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Acimaphin
Acinorphin
Addnok
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Johannes Kepler University Linz
Internal Medicine IV - Department of Pulmonology
Linz, Austria
Stadt Wien Wiener Gesundheitsverbund
Department of Respiratory and Lung diseases
Perchtoldsdorf, Austria
Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
Department of Pneumology/Respiratory Medicine
Salzburg, Austria
Sponsor: Vicore Pharma AB
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.